Search company, investor...


Founded Year



Corporate Minority - P2P | IPO

Total Raised


Market Cap


About KoBioLabs

KoBioLabs (KOSDAQ: 348150) is developing solutions in microbiome analysis, probiotics, and microbiome therapeutics. The company researches the specific genetic sequences of the gut microbiome related to these diseases and uses this genetic information to develop a pathogenic or therapeutic microbial biomarker. Its objective is to use these biomarkers to evaluate the healthy gut microbial community and develop a rapid and precise diagnostic technology.

Headquarters Location

Room 628, Building 220, Seoul National University, 1 Gwanak-ro

Seoul, 08826,

South Korea

+82 02)888-9964

Missing: KoBioLabs's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: KoBioLabs's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing KoBioLabs

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

KoBioLabs is included in 5 Expert Collections, including Omics.



1,542 items


Medical Devices

8,562 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Health Monitoring & Diagnostics

3,237 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Health IT

7,901 items

KoBioLabs Patents

KoBioLabs has filed 1 patent.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Inflammations
  • Allergology
patents chart

Application Date

Grant Date


Related Topics




Diseases of liver, Hepatology, Nutrition, Inflammations, Hepatitis


Application Date


Grant Date



Related Topics

Diseases of liver, Hepatology, Nutrition, Inflammations, Hepatitis



Latest KoBioLabs News

Week in Review: Fosun Pharma Acquires Majority Stake in China Vaccine Company for $682 Million

Oct 30, 2021

publication date: Oct 30, 2021  |  Deals and Financings Shanghai Fosun Pharma (SHA: 600196; HK: 02196) announced a $628 million deal to acquire a 73% stake in Chengdu Antejin Biotech, a vaccine company (see story ). Fosun paid $174 million to nine Antejin shareholders, and it contributed its own vaccine subsidiary, Dalian Aleph Biomedical at a value of $454 million, for the remainder. Antejin is developing a 13-valent pneumonia vaccine intended for infants, a competitor to Pfizer’s Prevnar 13. In the  US , Pfizer’s Prevnar 20 was recently approved to launch while Antejin is developing a 24-valent pneumonia conjugate candidate. SPH SINE, a subsidiary of  China China Korea 's KoBioLabs in a $110 million deal (see story ). SPH SINE made an upfront payment of $2.5 million, with the rest of the licensing fee payable for milestones. The two candidates are KBL697, which is aimed at psoriasis and IBD, and  KBL693, which is aimed at atopic dermatitis and asthma. Both products are preparing for US Phase II trials. KoBioLabs will transfer the technology for the two candidates to SPH SINE, which will be responsible for  China  trials and commercialization. Novadip Biosciences of Belgium raised $22 million in a Series B round from global investors including CR-CP Life Science Fund of Hong Kong (see story ). Novadip is a clinical stage company developing products to regenerate impaired skeletal tissue. Its proprietary 3M3 platform is a 3-dimensional, extracellular matrix that uses adipose-derived stem cells to deliver growth factors and miRNAs that mimic natural healing. The company's lead candidate is an autologous bone product aimed at diseases that include congenital pseudarthrosis of the tibia (CPT), a rare pediatric disease. Silenseed, a Tel Aviv RNAi company, raised $7.8 million from the Guangzhou Sino-Israel Bio-Industry Investment Fund to start a China JV (see story ). Silenseed-China will own the rights to develop, market and sell Silenseed’s RNAi products in  China . The Israeli company will use the capital to conduct a Phase III trial of its lead candidate, which targets the KRAS oncogene to treat pancreatic cancer. Silenseed's novel drug delivery platform enables the insertion of RNAi therapeutics directly into solid tumors. GIBF will own a 49% stake in the Silenseed Chinese subsidiary. SciNeuro, a Shanghai-Maryland CNS biopharma, formed a multi-program collaboration with  Switzerland 's Mabylon AG to discover auto-antibodies for neurological diseases (see story ). The two companies will collaborate on targets that include TAR DNA binding protein-43 (TDP-43) and Apolipoprotein E (APOE), which are potential treatments for ALS and Alzheimer’s disease. SciNeuro will have rights to develop and commercialize any products within Greater China with an option for global rights. Specific financial details of the agreement were not disclosed. CANbridge, a  Beijing  rare disease-focused biopharma, entered a research collaboration and license agreement with Scriptr Global to develop a gene therapy for dystrophinopathies (see story ). Scriptr is a preclinical Cambridge MA company that develops therapies for dystrophinopathies based on its proprietary ribozyme-mediated RNA assembly technology, CANbridge will gain exclusive global rights to a gene therapy candidate that uses Scriptr’s Stitchr™ platform and is aimed at X-linked genetic muscular diseases, which include several rare childhood diseases. Deals and Financings  Suzhou Alphamab Oncology (HK: 9966) started a China Phase II/III trial of its PD-L1/CTLA-4 bispecific antibody in patients with NSCLC who progressed after an anti-PD-L1 treatment (see story ). In the Phase III part of the trial, Alphamab will recruit about 486 patients aimed at OS and PFS as co-primary endpoints. In the trial, KN046 will be combined with lenvatinib and compared to docetaxel. The BLA for the PD-L1 alone has been accepted in China for microsatellite instability-high (MSI_H) and granted priority review. Suzhou Innovent (HK: 01801) and Shenzhen NeoCura will test a combination of Innovent's PD-1, sintilimab, and NeoCura's individual neoantigen mRNA vaccine in patients with solid tumor cancers (see story ). NeoCura's NEO_PLIN2101, a mRNA vaccine encoded corresponding neoantigen, is synthesized in vitro and vaccinated into patients to activate tumor-specific T cells. The company believes its patient-based vaccine has better specificity and immunogenicity than other therapies. Innovent will conduct a  China CANbridge, a  Beijing  rare disease/cancer biopharma, dosed the first patient in a China Phase II trial in patients with glioblastoma multiforme (see story) . CAN008 is a CD95 Fc fusion protein that blocks the interaction between CD95 receptor and its cognate ligand CD95L by binding to CD95L. The trial will investigate efficacy and explore select biomarkers. CANbridge in-licensed greater  China

KoBioLabs Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

KoBioLabs Rank

KoBioLabs Frequently Asked Questions (FAQ)

  • When was KoBioLabs founded?

    KoBioLabs was founded in 2014.

  • Where is KoBioLabs's headquarters?

    KoBioLabs's headquarters is located at Room 628, Building 220, Seoul National University, 1 Gwanak-ro, Seoul.

  • What is KoBioLabs's latest funding round?

    KoBioLabs's latest funding round is Corporate Minority - P2P.

  • How much did KoBioLabs raise?

    KoBioLabs raised a total of $35.99M.

  • Who are the investors of KoBioLabs?

    Investors of KoBioLabs include e-mart, CJ Investment, Atinum Investment, Company K Partners, Stonebridge Ventures and 12 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.